Pacer Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $121M | Sell |
660,408
-485,482
| -42% | -$89.5M | 0.34% | 67 |
|
|
2025
Q4 | $202M | Sell |
1,145,890
-305,359
| -21% | -$49.9M | 0.52% | 49 |
|
|
2025
Q3 | $203M | Buy |
1,451,249
+131,258
| +10% | +$17.7M | 0.51% | 49 |
|
|
2025
Q2 | $166M | Sell |
1,319,991
-32,569
| -2% | -$4.06M | 0.41% | 56 |
|
|
2025
Q1 | $185M | Sell |
1,352,560
-1,314,971
| -49% | -$188M | 0.43% | 58 |
|
|
2024
Q4 | $408M | Buy |
2,667,531
+2,648,024
| +13,575% | +$447M | 0.88% | 25 |
|
|
2024
Q3 | $3.78M | Buy |
19,507
+441
| +2% | +$92.3K | 0.01% | 737 |
|
|
2024
Q2 | $4.42M | Buy |
19,066
+2,149
| +13% | +$467K | 0.01% | 618 |
|
|
2024
Q1 | $3.65M | Sell |
16,917
-12,012
| -42% | -$2.81M | 0.01% | 672 |
|
|
2023
Q4 | $7.49M | Buy |
28,929
+12,343
| +74% | +$3.03M | 0.02% | 473 |
|
|
2023
Q3 | $4.26M | Buy |
16,586
+1,806
| +12% | +$483K | 0.02% | 488 |
|
|
2023
Q2 | $4.21M | Sell |
14,780
-2,180
| -13% | -$649K | 0.02% | 554 |
|
|
2023
Q1 | $4.72M | Buy |
16,960
+12,157
| +253% | +$3.36M | 0.02% | 552 |
|
|
2022
Q4 | $1.33M | Sell |
4,803
-342,262
| -99% | -$96.7M | 0.01% | 698 |
|
|
2022
Q3 | $92.7M | Sell |
347,065
-140,561
| -29% | -$29.9M | 0.65% | 41 |
|
|
2022
Q2 | $99.4M | Buy |
487,626
+163,478
| +50% | +$33.4M | 0.74% | 32 |
|
|
2022
Q1 | $68.3M | Buy |
324,148
+311,731
| +2,511% | +$67.8M | 0.56% | 42 |
|
|
2021
Q4 | $2.98M | Sell |
12,417
-3,235
| -21% | -$832K | 0.03% | 653 |
|
|
2021
Q3 | $4.43M | Sell |
15,652
-39,494
| -72% | -$12.9M | 0.06% | 467 |
|
|
2021
Q2 | $19.1M | Buy |
55,146
+18,151
| +49% | +$5.5M | 0.27% | 52 |
|
|
2021
Q1 | $10.3M | Buy |
36,995
+1,160
| +3% | +$313K | 0.18% | 78 |
|
|
2020
Q4 | $8.78M | Sell |
35,835
-4,560
| -11% | -$1.18M | 0.16% | 91 |
|
|
2020
Q3 | $11.5M | Sell |
40,395
-2,053
| -5% | -$573K | 0.24% | 73 |
|
|
2020
Q2 | $11.4M | Buy |
42,448
+15,024
| +55% | +$4.52M | 0.23% | 77 |
|
|
2020
Q1 | $9.39M | Buy |
27,424
+13,210
| +93% | +$4.01M | 0.19% | 49 |
|
|
2019
Q4 | $4.22M | Sell |
14,214
-40,427
| -74% | -$11.2M | 0.19% | 86 |
|
|
2019
Q3 | $12.7M | Buy |
54,641
+880
| +2% | +$205K | 0.29% | 62 |
|
|
2019
Q2 | $12.6M | Buy |
53,761
+10,251
| +24% | +$2.37M | 0.31% | 55 |
|
|
2019
Q1 | $10.3M | Buy |
43,510
+32,680
| +302% | +$10.3M | 0.29% | 62 |
|
|
2018
Q4 | $3.26M | Sell |
10,830
-17,519
| -62% | -$5.59M | 0.11% | 33 |
|
|
2018
Q3 | $10M | Buy |
28,349
+8,950
| +46% | +$3.08M | 0.38% | 43 |
|
|
2018
Q2 | $5.63M | Buy |
19,399
+5,729
| +42% | +$1.61M | 0.25% | 55 |
|
|
2018
Q1 | $3.74M | Buy |
13,670
+2,023
| +17% | +$628K | 0.21% | 76 |
|
|
2017
Q4 | $3.71M | Buy |
11,647
+3,662
| +46% | +$1.17M | 0.26% | 61 |
|
|
2017
Q3 | $2.5M | Buy |
7,985
+957
| +14% | +$283K | 0.22% | 67 |
|
|
2017
Q2 | $1.91M | Buy |
7,028
+667
| +10% | +$176K | 0.19% | 73 |
|
|
2017
Q1 | $1.74M | Buy |
6,361
+183
| +3% | +$51.7K | 0.21% | 60 |
|
|
2016
Q4 | $1.75M | Sell |
6,178
-59
| -0.9% | -$17.5K | 0.25% | 58 |
|
|
2016
Q3 | $1.95M | Sell |
6,237
-150
| -2% | -$44.4K | 0.3% | 52 |
|
|
2016
Q2 | $1.54M | Buy |
6,387
+191
| +3% | +$50.3K | 0.24% | 60 |
|
|
2016
Q1 | $1.61M | Sell |
6,196
-5
| -0.1% | -$1.32K | 0.37% | 56 |
|
|
2015
Q4 | $1.9M | Buy |
+6,201
| New | +$1.78M | 0.45% | 50 |
|
|
2013
Q4 | $204K | Buy |
+600
| New | +$155K | 0.05% | 477 |
|
Other funds holding BIIB
VCM
VPM
Pacer Advisors's BIIB Position: Q1 2026 in Review
Pacer Advisors reduced its Biogen (BIIB) stake by 42% in Q1 2026, selling an estimated $89.5M and leaving 660,408 shares worth $121M. The position accounts for 0.34% of the portfolio, ranked #67.
Pacer Advisors first reported a position in BIIB in Q4 2013 and has held it in 43 quarters since. The position peaked at $408M in Q4 2024. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Pacer Advisors held 660,408 shares of Biogen worth $121M as of Q1 2026.
- Pacer Advisors sold 485,482 Biogen shares in Q1 2026, an estimated $89.5M.
- Biogen made up 0.34% of Pacer Advisors's portfolio in Q1 2026, its #67 holding.
- Pacer Advisors first reported a position in Biogen in Q4 2013 and has held it in 43 quarters since.
- Pacer Advisors's Biogen position peaked at $408M in Q4 2024.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.